Precision Digital Health’s CEO and Cofounder, Thomas Wells, presented their SUMMA™ Real-World Evidence Interoperability Platform at the HL7® FHIR® Applications Roundtable at the Harvard Medical School in Boston. Our platform provides an end-to-end solution to enable researchers to ask and validate questions they never could ask before. Our interoperable SUMMA™ platform enables the convergence of real-world patient data from many sources like electronic health records (EHR), as well as device data from medical devices and wearables, to support real-world and pragmatic clinical trials. SUMMA™ provides a configurable end-to-end solution that provides value immediately to follow patients in a real-world setting by leveraging interoperability of health systems via HL7® FHIR® to identify and follow patients in a next generation clinical trial system. By providing these enabling capabilities across different data assets like genomics, labs, medical devices, wearables and EMR systems we empower clinical teams for their research.
About Precision Digital Health:
Precision Digital Health is a disruptive global solution provider for clinical trials, Health Economics & Outcomes Research (HEOR). and real-world evidence research to accelerate patient outcomes. Our solutions integrate and precisely assess patients in the real-world to support novel patient-centric endpoints in near real-time. By combining patient data sourced via wearables, genomics, and EHR systems we reduce time and costs in outcomes research while surfacing clinical insights with advanced analytics in novel disease areas.
